Extended Data Fig. 6: Bone marrow-derived granulocyte induce increasing systemic LCN2 levels in plasma and inflammatory activation of astrocytes.

a. qPCR analysis of Lcn2 expression in different cell populations sorted from bone marrow of normal C57BL/6 males: CD45-, CD45+CD11b+Ly6CinterLy6G+ granulocytes, CD45+CD11b+Ly6C+Ly6G- monocytes, CD45+CD11b-CD3+ B220- T cells, CD45+CD11b-CD3-B220+ B cells. Dots represent individual mice (n = 4 mice per group), line indicates median, whisker shows mean to max (one-way ANOVA). b. ‘LCN2 BM contribution’ calculated by expression of LCN2 in different cell populations from a, multiplied by their abundance in BM from Extended Data Fig. 5b. Results are presented as percent of total. c. LCN2 ELISA in blood, one and two weeks following BMT. Dots represent individual mice, error bars represent s.e.m., (WT n = 9, Lcn2-/- n = 9 mice) (one-way ANOVA). d. LCN2 levels in blood of mice at endpoint measured by ELISA, (WT n = 7, Lcn2-/- n = 7 mice), dots represent individual mice, error bars represent s.e.m. (Student’s t-test, two-sided). e. Expression level of inflammatory gene signature measured by qPCR in RNA of FACS sorted astrocytes in vivo from WT mice that underwent BMT as described in (Fig. 4a). Dots represent individual mice, line indicates median, plot shows mean to max (Ctrl n = 4, WT n = 6, Lcn2-/- n = 6 mice) (two-way ANOVA).